Hallmark | Marker | COPD versus non-COPD | COPD cell origin | CSE-treated cells | References |
Genomic instability | γ-H2A.X | ↑ | Lung tissue sections, AT1, AT2, HBEC and PV-EC | HBEC, HFL1 and MRC-5 | [75, 76, 78, 79] |
Ku70 | ↓ | Peripheral leukocytes | [80] | ||
Ku80 | ↓ | Lung homogenates | [77] | ||
Telomere shortening | Length | ↓ | Lung homogenates AT2, PA-SMC, PV-EC and peripheral leukocytes | SAEC (COPD) and HFL1 | [78, 81–86] |
Telomerase | ↓ | PV-EC | [84] | ||
TPP1 | ↓ | Lung homogenates | SAEC and HFL1 | [78] | |
Epigenetic changes | HDAC activity | ↓ | Lung homogenates and bronchial biopsies | [92] | |
SIRT1 and -6 | ↓ | Lung homogenates | [94, 95] | ||
Loss of proteostasis | Autophagy | ↑ | HBEC | SAEC | [100] |
Autophagy | ↓ | HBEC (COPD) | [100] | ||
Autophagosomes | ↑ | Lung homogenates | HBEC and BEAS-2B | [79, 99, 100] | |
Ubiquitin | ↑ | Lung homogenates | [98, 100] | ||
p62 | ↑ | Lung homogenates | [79, 100] | ||
Deregulated nutrient sensing | S6K (mTOR) | ↑# | Lung homogenates and peripheral leukocytes | HBEC | [79, 103] |
IGF1 | ↑ | SAEC | [104] | ||
Mitochrondrial dysfunction | ROS | ↑ | HBEC, BEAS-2B and MRC-5 | [76, 108, 109] | |
Oxidised DNA | ↑ | Lung homogenates | [77] | ||
Lipid peroxidation | ↑ | Lung homogenates | [105, 106] | ||
Nitric oxide | ↑ | Lung homogenates | [106] | ||
Mitophagy | ↑ | Lung homogenates | HBEC and BEAS-2B | [108, 109] | |
Antioxidant | ↓ | Lung homogenates and HBEC | [107] | ||
Mitochondrial membrane potential | ↓ | BEAS-2B | [108] | ||
Immune dysregulation | Klotho | ↓ | Lung homogenates | HBEC | [112] |
NF-κB | ↑ | Lung homogenates | [113] | ||
Pro-inflammatory cytokines | ↑ | Lung homogenates | [113] | ||
Senescence | SA-β-gal | ↑ | SAEC, PA-SMC, PV-EC and fibroblasts | SAEC (COPD), HBEC, A549, HFL1 and MRC-5 | [76, 78, 79, 84–86, 115–117] |
p16 | ↑ | Lung tissue sections, AT1, AT2, PA-SMC, PV-EC and fibroblasts | HFL1 | [75, 76, 78, 84–86, 116, 117] | |
p21 | ↑ | Lung homogenates, AT2, PA-SMC, PV-EC and peripheral leukocytes | HBEC, A549 and HFL1 | [78–80, 84–86, 117] | |
IL-6 and IL-8 | ↑ | Lung tissue sections, AT1, AT2, PA-SMC and PV-EC | MRC-5 | [75, 76, 84, 85] | |
ECM dysregulation | ECM proteins | ↑ | Lung homogenates | [42] | |
Elastogenesis genes | ↑ | Lung homogenates | [125] | ||
MMP/TIMP dysregulation | ↑ | Lung homogenates | [123] | ||
Stem cell exhaustion | Circulating progenitor cells | ↓# | Endothelial and haemopoietic progenitor cells | [137, 138] | |
Regenerative capacity | ↓ | Basal progenitor cells | [135] | ||
Stem cell function | ↓ | HBEC | [142] | ||
WNT signalling | ↓# | Lung homogenates, AT2 and SAEC | [144, 147] | ||
Notch pathway | ↓# | SAEC | [143] |
CSE: cigarette smoke extract; AT1: type I alveolar cells; AT2: type II alveolar cells; HBEC: human bronchial epithelial cells; PV-EC: pulmonary vascular endothelial cells; HFL1: fetal lung fibroblasts; MRC-5: fetal lung fibroblasts; TPP1: telomere protection protein 1; PA-SMC: pulmonary artery smooth muscle cells; SAEC: small airway epithelial cells; HDAC: histone deacetylase; SIRT: sirtuin; BEAS-2B: bronchial epithelial cell line (virus); mTOR: mechanistic target of rapamycin; IGF1: insulin-like growth factor 1; ROS: reactive oxygen species; SA-β-gal: senescence-associated-β-galactosidase; IL: interleukin; A549: alveolar basal epithelial cell line (carcinoma); ECM: extracellular matrix; MMP: matrix metalloproteinase; TIMP: tissue inhibitor of metalloproteinase. #: mean age was significantly different between COPD and control group; for the other studies, information was not available or mean age was not different between groups.